These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 18379730)

  • 1. Clinical trials and biomarker development with molecularly targeted agents and radiotherapy.
    Dhani N; Siu LL
    Cancer Metastasis Rev; 2008 Sep; 27(3):339-49. PubMed ID: 18379730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New science-based endpoints to accelerate oncology drug development.
    Kelloff GJ; Sigman CC
    Eur J Cancer; 2005 Mar; 41(4):491-501. PubMed ID: 15737552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecularly targeted therapies for malignant gliomas: advances and challenges.
    Penas-Prado M; Gilbert MR
    Expert Rev Anticancer Ther; 2007 May; 7(5):641-61. PubMed ID: 17492929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical biomarkers of kinase activity: examples from EGFR inhibition trials.
    Krause M; Baumann M
    Cancer Metastasis Rev; 2008 Sep; 27(3):387-402. PubMed ID: 18427731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice.
    Kinders R; Parchment RE; Ji J; Kummar S; Murgo AJ; Gutierrez M; Collins J; Rubinstein L; Pickeral O; Steinberg SM; Yang S; Hollingshead M; Chen A; Helman L; Wiltrout R; Simpson M; Tomaszewski JE; Doroshow JH
    Mol Interv; 2007 Dec; 7(6):325-34. PubMed ID: 18199854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers.
    Lee JW; Figeys D; Vasilescu J
    Adv Cancer Res; 2007; 96():269-98. PubMed ID: 17161683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic biomarkers for molecular cancer therapeutics.
    Sarker D; Workman P
    Adv Cancer Res; 2007; 96():213-68. PubMed ID: 17161682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of molecular biomarkers for predicting the response to radiotherapy with or without chemotherapy.
    Riesterer O; Milas L; Ang KK
    J Clin Oncol; 2007 Sep; 25(26):4075-83. PubMed ID: 17827456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarkers for DNA DSB inhibitors and radiotherapy clinical trials.
    Liu SK; Olive PL; Bristow RG
    Cancer Metastasis Rev; 2008 Sep; 27(3):445-58. PubMed ID: 18516501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From darkness to light with biomarkers in early clinical trials of cancer drugs.
    Carden CP; Banerji U; Kaye SB; Workman P; de Bono JS
    Clin Pharmacol Ther; 2009 Feb; 85(2):131-3. PubMed ID: 19151637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents.
    Le Tourneau C; Vidal L; Siu LL
    Drug Resist Updat; 2008 Jun; 11(3):99-109. PubMed ID: 18515176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 0 clinical trials in oncology: a paradigm shift for early drug development?
    Takimoto CH
    Cancer Chemother Pharmacol; 2009 Mar; 63(4):703-9. PubMed ID: 18615251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Possibilities and limitations of stratified medicine based on biomarkers and targeted therapies in oncology].
    Ludwig WD
    Z Evid Fortbild Qual Gesundhwes; 2012; 106(1):11-22. PubMed ID: 22325103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarkers of clinical trials using molecular inhibitors and radiotherapy: state-of-the-art. Preface.
    Bristow RG
    Cancer Metastasis Rev; 2008 Sep; 27(3):337-8. PubMed ID: 18427733
    [No Abstract]   [Full Text] [Related]  

  • 15. Is tailored therapy feasible in oncology?
    Gasparini G; Longo R; Torino F; Gattuso D; Morabito A; Toffoli G
    Crit Rev Oncol Hematol; 2006 Jan; 57(1):79-101. PubMed ID: 16337806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. End points in cancer clinical trials and the drug approval process.
    Schilsky RL
    Clin Cancer Res; 2002 Apr; 8(4):935-8. PubMed ID: 11948095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecularly targeted oncology therapeutics and prolongation of the QT interval.
    Strevel EL; Ing DJ; Siu LL
    J Clin Oncol; 2007 Aug; 25(22):3362-71. PubMed ID: 17664484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parallel anticancer drug development and molecular stratification to qualify predictive biomarkers: dealing with obstacles hindering progress.
    Garcia VM; Cassier PA; de Bono J
    Cancer Discov; 2011 Aug; 1(3):207-12. PubMed ID: 22586572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploitable mechanisms for combining drugs with radiation: concepts, achievements and future directions.
    Bentzen SM; Harari PM; Bernier J
    Nat Clin Pract Oncol; 2007 Mar; 4(3):172-80. PubMed ID: 17327857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarkers in drug development: friend or foe? A personal reflection gained working within oncology.
    Carroll KJ
    Pharm Stat; 2007; 6(4):253-60. PubMed ID: 17351904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.